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Abstract
Methods are presented for the use of the coral 8R-lipoxygenase from the Caribbean sea
whip coral Plexaura homomalla as a model enzyme for structural studies of animal
lipoxygenases. The 8R-lipoxygenase is remarkably stable and can be stored at 4°C for
3 months with virtually no loss of activity. In addition, an engineered “pseudo wild-type”
enzyme is soluble in the absence of detergents, which helps facilitate the preparation of
enzyme:substrate complexes.
1. INTRODUCTION
The discovery of prostaglandins in Plexaura homomalla in 1969
(Weinheimer & Spraggins, 1969) eventually led to the identification of
cyclooxygenase (COX) and lipoxygenase (LOX) biosynthetic pathways
in corals. While the functions of the oxylipins these enzymes generate
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remain undefined, P. homomalla 8R-LOX has proven to be a remarkably sta-
ble homologue of human 5-LOX, with which it shares 40% sequence
identity. This is the same level of sequence identity observed between
5-LOX and its closest intraspecies orthologue 15-LOX-2. Human
5-LOX is the only clinically validated drug target of the LOX family, but
the enzyme’s short half-life has made biochemical characterization difficult
(Carter et al., 1991; Percival, Denis, Riendeau, & Gresser, 1992; Wenzel
et al., 2007). The extraordinary stability of the coral enzyme makes it a
highly tractable system for structural studies, as protein instability is a
frequent roadblock to structural studies (Deller, Kong, & Rupp, 2016),
and 8R-LOX structures have revealed key mechanistic details of the
LOX oxygenation reaction. Although 8R-LOX was originally identified
as the C-terminal region of a naturally occurring fusion protein (Gilbert
et al., 2008; Koljak, Boutaud, Shieh, Samel, & Brash, 1997), we will focus
on the isolated LOX domain in this report (Boutaud & Brash, 1999; Brash,
Boeglin, Chang, & Shieh, 1996; Oldham, Brash, & Newcomer, 2005).
LOXs are nonheme iron enzymes that catalyze the regio- and stereospe-
cific dioxygenation of polyunsaturated fatty acids at a cis, cis-1,4-pentadiene
(Boutaud & Brash, 1999), often to generate a potent lipid-signaling medi-
ator. The enzymes have been found in animals, plants, bacteria, and fungi,
with certain species harboring a catalytic manganese instead of iron
(Andreou & Feussner, 2009; Boutaud & Brash, 1999; Hamberg, Su, &
Oliw, 1998; Kuhn & Thiele, 1999). The common substrate for animal
LOXs is arachidonic acid (AA), an ω6 20-carbon fatty acid with four
double bonds. There are 3 pentadienes in AA with the potential for
12 unique oxidation products that can be produced by a single LOX reaction
(Fig. 1A). The overall tertiary structure of plant (Boyington, Gaffney, &
Amzel, 1993) and animal (Gillmor, Villasenor, Fletterick, Sigal, &
Browner, 1997) LOXs shares a common fold. These LOXs contain an
N-terminal β-barrel domain of 15kDa, which may harbor Ca2+-binding
residues and membrane-insertion loops that target the enzyme to the mem-
brane periphery (Fig. 1B). The much larger (4) C-terminal domain of
LOX positions the catalytic iron at the base of a U-shaped cavity (Fig. 1C).
The Fe2+ is chelated by invariant histidines and the main chain carboxy
terminus (Minor et al., 1996; Newcomer & Brash, 2015; Skrzypczak-
Jankun, Bross, Carroll, Dunham, & Funk, 2001; Xu, Mueser, Marnett, &
Funk, 2012).
Our initial work with the 8R-LOX domain of the P. homomalla fusion
protein led to a 3.2 Å resolution structure (Oldham et al., 2005).
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Examination of crystal packing led us to suggest that a membrane-insertion
loop interfered with packing of the protein molecules in the crystal lattice.
We reasoned that removal of an extended hydrophobic loop, which pene-
trated a neighboring molecule, might facilitate a tightly packed lattice that
could provide us with higher resolution X-ray data (Fig. 1B). Deletion of
a membrane-insertion loop (8R-LOX Δ41-45GS) from the PLAT
(polycystin-1, LOX, Alpha-Toxin) domain of 8R-LOX by mutagenesis
yielded an enzyme with increased solubility (Fig. 2). The construct was
given the moniker “pseudo-wild type (psWT)” because it retains the
in vitro enzymatic activity of its progenitor, despite the lack of both a
membrane-binding loop and Ca2+-binding amino acids necessary for mem-
brane targeting (Neau, Gilbert, Bartlett, Dassey, & Newcomer, 2007). As
hoped, the mutant provided crystals that diffract to 1.9 Å resolution and
amenable to the manipulation required for an anaerobic enzyme:substrate
complex (Neau et al., 2014, 2009). The latter structure revealed the AA sub-
strate positioned in the U-shaped active site in a pose consistent with the
regio- and stereospecificity of 8R-LOX, and hence provided a robust model
Fig. 1 Lipoxygenase reaction and structure. (A) Arachidonic acid has three pentadienes
with hydrogens on carbon 7, 10, and 13 (smaller font and colored blue, red, and green,
respectively, or different shades of gray) that are possible sites of attack by LOX enzymes.
Notice in the online version of the figure that carbons are colored with respect to the
hydrogen that needs to be abstracted for oxygenation to occur at that carbon. For
example, hydrogen abstraction on carbon 10 (red) will result in oxygen addition at either
carbon 8 or 12 (both red), depending on the particular enzyme. (B) 8R-LOX WT (PDB
code 2fnq) and 8R-LOX psWT (PDB code 3fg1) are superimposed for comparison.
Membrane-insertion loops and Ca2+-binding residues have been deleted from the lat-
ter. Detailed view of N-terminal domain (framed box in panel C) with 8R-LOX WT shown
in blue or dark gray and 8R-LOX psWT shown inwhite. Spheres are bound Ca2+ as seen in
the 8R-LOX WT structure. Residues (blue/dark gray) that are highlighted are either Ca2+-
binding residues 43–45 (His-Asn-Asp) or membrane-insertion residues 41–42 (Trp-Phe).
Residues shown in white are membrane-binding residues Tyr 77 and Trp 78. (C) Cartoon
rendering of 8R-LOX WT shown in blue or dark gray and 8R-LOX psWT shown in white.
The catalytic domain is mainly α-helical and harbors the catalytic iron (orange/gray
sphere).
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for understanding LOX product specificity in this superfamily
(Newcomer & Brash, 2015). The protein engineering strategy of removing
a LOX membrane-insertion loop has been applied to additional LOX
(Mittal et al., 2017) and yielded a protein amenable to crystallization
(Gilbert et al., 2011).
2. PREPARATION OF HIGHLY PURIFIED 8R-LOX
Having homogenous and monodisperse protein is generally an impor-
tant prerequisite for obtaining diffraction-quality crystals suitable for high-
resolution structure determination. For the case of 8R-LOX, an ample
amount of protein can be expressed in Escherichia coli with low temperature
incubation of the cultures in the autoinduction media first described by
Studier (2005).
2.1 Transformation of 8R-LOX psWT Into Overexpression Host
The pET-3a plasmid harboring 8R-LOX psWT is transformed into BL21
(DE3) cells using the heat-shock protocol.
2.1.1 Equipment
• 42°C water bath for heat-shock transformation
• 37°C benchtop shaking incubator
• 37°C incubator for overnight incubation of agar plates
2.1.2 Buffers and Reagents
• E. coli BL21 (DE3) cells (Invitrogen)
Fig. 2 Sequence alignment of four human lipoxygenases with the coral 8R-LOX and
its deletion mutant psWT. The PDB codes are included if a sequence from a solved
protein structure was used. The box frames the area of the protein sequence where
Ca2+-binding residues and membrane-insertion residues were mutated. The * repre-
sents amino acids that bind Ca2+ in the N-terminal domain. The • represents amino acids
known to peripherally bind themembrane. The amino acid sequenceWFHND of 8R-LOX
wasmutated to GS to generate 8R-LOX psWT. The amino acid sequence PFYND of 5-LOX
was mutated to GS to generate a soluble 5-LOX known as Stable-5-LOX.
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• SOC media—2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM
KCl, 10mM MgCl2, 10mM MgSO4, and 20mM glucose (Invitrogen)
• Luria–Bertani (LB) broth with 10g peptone, 5g yeast extract, and 5g
NaCl (Research Products International)
• Carbenicillin (100μg/mL final concentration) (P212121)
2.1.3 Procedure
1. 10μL of E. coli BL21 (DE3) cells are thawed on ice. 50ng of plasmid
DNA is added to thawed cells and tube is flicked 4–5 times to mix
the cells.
2. The mixture is incubated on ice for 5min.
3. The mixture is placed in a 42°C bath for 45 s and returned back to ice for
2min.
4. 200μL of prewarmed SOCmedia is added, and the mixture is transferred
to a 14-mL round bottom falcon tube.
5. The tube is placed at 37°C for 45min in incubator and is vigorously
rotated.
6. The mixture is plated on LB plate with carbenicillin and incubated over-
night at 37°C.
2.1.4 Notes
1. Transformation efficiency is reduced with multiple freeze/thaw cycles of
the competent cells.
2. We routinely only use 10μL of competent cells, which is one-fifth of the
volume aliquoted by the supplier. The other portion of competent cells
is transferred to sterile 1.5-mL microcentrifuge tubes in aliquots of 10μL
and placed in 80°C.
3. We do not store glycerol stocks of transformed bacteria as they do not
necessarily provide the generous yields that freshly transformed bacteria
do. We invariably start each preparation with freshly transformed cells.
2.2 Expression of 8R-LOX
2.2.1 Equipment
• Large, high-capacity floor model orbital shaker with refrigeration capa-
bilities (Infors HT, Multitron model)
• Standard SDS-PAGE equipment, 10% SDS-PAGE gels
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2.2.2 Buffers and Reagents
• Autoinducing media ZYM-5052 is a media for growing high-density
shake-flask cultures that upon saturation will autoinduce protein expres-
sion (Studier, 2005). ZYM-5052 contains:
i. 1% N-Z-amine AS, 0.5% yeast extract, abbreviated ZY and is
autoclaved separately
ii. 25mM Na2HPO4, 25mM KH2PO4, 50mM NH4Cl, 5mM
Na2SO4, abbreviated 50M and is autoclaved separately at 50
concentration
iii. 2mM MgSO4, made at a concentration of 1.0 M and autoclaved
separately
iv. 0.5% glycerol, 0.05% glucose, 0.2% α-lactose, abbreviated as
505052, made at 50 concentration, and sterile filtered
• Optional: IPTG (isopropyl β-D-1-thiogalactopyranoside) used at
500μM final concentration (Research Products International)
2.2.3 Procedure
1. A single colony from the plate is used to inoculate (2) 25mL LB in
125-mL Erlenmeyer flask with carbenicillin for selection.
2. Shake flasks are grown overnight in the incubator at 220 rpm, 37°C.
3. (8) 480mL of ZY media is prepared in a nonbaffled 2-L Erlenmeyer
flask the day before inoculation along with stocks of 1.0 M MgSO4,
50M, and 505052. (Pro hint: LOX expression is very sensitive to
aeration of the media. Flask size, baffles vs nonbaffles, and temperature
along with rpm should be followed carefully according to protocol).
4. 2.0mL of the overnight culture is added to each flask along with 10mL
of 50M and 505052, and 1mL of 1.0 M MgSO4.
5. Cultures are grown at 37°C, 220rpm for 4h.
6. The temperature is dropped to 20°C and grown overnight. On the next
morning, the optical density of the cultures is monitored by absorbance
at 600nm. It is key to make sure that the bacterial growth is past log phase
and has entered the stationary phase otherwise autoinduction does not
occur. Upon saturation of culture, lactose is transported inside the bac-
terial cell, and β-galactosidase converts the lactose to allolactose. All-
olactose induces expression of the protein of interest by binding the
lac repressor, which now allows T7 RNA polymerase to bind the lac
promoter and produce the mRNA transcripts for 8R-LOX psWT.
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7. The cells usually reach saturation that afternoon and are harvested and
centrifuged at 5000 g for 10min. Pellets are frozen at 80°C until
further use.
2.2.4 Notes
1. IPTGmay be added 4h before harvest if uncertain about having reached
a stationary phase and therefore having undergone autoinduction over-
expression of 8R-LOX psWT.
2. Protein expression can be checked by taking a 1-mL sample of growth at
harvest. The sample is spun down at 13,000rpm in microcentrifuge.
A volume of 300μL of Bugbuster® is added and then incubated at
4°C while nutating for 1h. Soluble and insoluble material is separated
by centrifugation at 13,000rpm and samples are run on SDS-PAGE
gel. 8R-LOX psWTmigrates75kDa and should appear in the soluble
fraction.
2.3 Purification of 8R-LOX
This three-step purification can be completed in 2 days and yields highly
purified enzyme (10mg enzyme per 1L of expression media) that is ame-
nable to high-resolution structural studies (Fig. 3).
2.3.1 Equipment
• Branson Sonifier 250 (VWR Scientific)
• FRENCH® Pressure cell press (SLM Instruments, Inc. of Milton Roy
company)
• Nalgene syringe filter, 25mm cellulose acetate membrane, 0.8μm
(ThermoFisher Scientific)
• DynaLoop 90, store in 20% ethanol (Bio-Rad)
• AKTA FPLC (GE Healthcare Life Sciences)
• HisTrap HP 5mL column (GE Healthcare Life Sciences)
• Dialysis tubing with average flat width 25mm, 14kDa cutoff (Sigma).
Tubing is washed under running water for 2min before use. Residual
glycerin and sulfur compounds from dialysis tubing do not appear to
affect purification of the 8R-LOX psWT protein.
• Mono-Q (10/100 GL) anion exchange (GE Healthcare Life Sciences)
• Spin-X® UF 20mL Concentrator 30,000 molecular weight cutoff
(Corning)
• Nanodrop™ 2000 Spectrophotometer (ThermoFisher Scientific)
Molecular weight of protein is 79,000Da and theoretical molecular
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Fig. 3 Purification of 8R-LOX psWT by immobilizedmetal-affinity chromatography. The y-axis is themilli-absorbance at 280nm, and x-axis the
elution volume. Cell lysate (80mL) was loaded onto a HisTrap HP 5mL column followed by 100mL of wash with equilibration buffer. Bound
8R-LOX psWT is eluted by a gradient of increasing concentration of buffer B (200mM imidazole). Fractions 4 through 7 were collected and
used for further purification.
extinction coefficient that is used is 137,000 for measuring protein
concentration.
• Hiload 16/600 Superdex 200 10/300 PG (GE Healthcare Life Sciences)
• Vial Clamp™ curved (Hampton Research)
• Long-handled tweezers with serrated tip and furrowed handle (Grainger)
• Low form shallow dewar with hemispherical bottom (Pope Scientific
Inc.) (see Fig. 4)
2.3.2 Buffers and Reagents
• Bugbuster®, bacterial chemical lysis reagent with detergent (Novagen)
• DNase I from bovine pancreas (Sigma)
• Leupeptin (5μg/mL final concentration), pepstatin (10μM final concen-
tration, Sigma), and PMSF (phenylmethylsulfonyl fluoride, Sigma)
• Immobilized affinity chromatography (IMAC) buffer A: 20mM Tris pH
8.0/500mM NaCl/20mM imidazole pH 8.0
• IMAC buffer B: 20mM Tris pH 8.0/500mMNaCl/200mM imidazole
pH 8.0
• Anion-exchange buffer A: 20mM Tris pH 8.0
• Anion-exchange buffer B: 20mM Tris pH 8.0 and 500mM NaCl
• Size exclusion chromatography (SEC) buffer: 20mM Tris pH 8.0 and
150mM NaCl
Fig. 4 Cryocooling of purified 8R-LOX psWT. The low form shallow dewar with hemi-
spherical bottom is shown without liquid N2. The curved vial clamp™ and tweezers
have been placed on top of the dewar. Inset in bottom left corner shows protein that
has been cryocooled in the liquid N2, collected by long-handled tweezers, and placed
into cryocooled microcentrifuge tube that is held by the curved vial clamp™. Protein
beads are not clearly discerned due to fogging of cryocooled tube.
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2.3.3 Procedure
1. Cell pellets containing expressed 8R-LOX psWT are weighed out in a
250-mL plastic beaker. Typical growth from 4L of media results in
45g of cell pellet.
2. Bugbuster® is added at customized ratio of 2.0mL of Bugbuster® per
1.0g of cell pellet. Manufacturer recommends 5.0mL of Bugbuster®
per 1.0g of cell pellet.
3. DNase I (100 Kunitz) is added along with PMSF (2mg of crystalline
material), pepstatin, and leupeptin. The solution is homogenized on a
stir plate for 10min in an ice-bath.
4. Mixture can either be:
a. Sonicated (3) for 2min, 50% duty, and output control of 8 out of
10 on Branson Sonifier 250. Between cycles of sonication, mixture
is cooled on ice for 5min.
b. French pressed with pressure >16,000psi on FRENCH® Pressure
cell press. The French pressure system that is utilized allows
40mL of mixture to be pressed per pass. Typical output time is
5min per 40mL. Once the mixture is passed through the press,
the solution is immediately placed in an ice-bath. Note: French
press lysis yields larger amounts of protein due to better lysis of cells
and less loss due to denaturation.
5. Mixture is centrifuged at 40,000 g for 45min at 4°C to clarify lysate
and to pellet insoluble portion.
6. Supernatant is filtered by 0.8-μm syringe filter and loaded onto super-
loop (DynaLoop 90).
7. HisTrap HP 5mL column is equilibrated with 20mM Tris pH
8.0/500mM NaCl/20mM imidazole pH 8.0 on FPLC until UV and
conductivity are stable baselines (usually 5 column volumes, make sure
to pH both Tris and imidazole).
8. Supernatant from superloop is loaded onto column at 2mL/min.
9. Column with bound protein is washed with 100mL of equilibration
buffer.
10. Protein is eluted using a linear gradient of 100% B over 20 column vol-
umes with 5mL fractions. Buffer B is similar to equilibration buffer but
with 200mM imidazole pH 8.0.
11. Fractions that contain protein as monitored by absorbance at 280nm
are collected from the middle of the Gaussian peak. Shoulder fractions
lower than one-third of the peak height are discarded.
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12. Peak fractions are pooled and placed in dialysis tubing and dialyzed
overnight in 2L of 20mM Tris pH 8.0 in cold room.
13. The next day, the Mono-Q anion-exchange column is equilibrated
with 20mM Tris pH 8.0 on the FPLC until the UV and conductivity
signals have stable baselines.
14. Protein that was dialyzed overnight is syringe filtered and loaded onto
cleaned superloop.
15. Protein is injected onto Mono-Q from the superloop at 2mL/min and
the column is washed with 40mL (5 column volumes) of equilibration
buffer.
16. Protein is eluted with linear gradient from 0% to 100% B over 10 col-
umn volumes with 5mL fractions. Buffer B contains 20mM Tris pH
8.0 and 500mM NaCl.
17. Once again fractions that contain protein as indicated by A280 are col-
lected from the middle of the Gaussian peak using a similar shoulder
cutoff.
18. Peak fractions are pooled and concentrated in Spin-X® UF 20mL
Concentrator with 30,000 molecular weight cutoff. Protein is concen-
trated to 2mL and 20mg/mL as measured on a Nanodrop™.
19. Protein is loaded onto 2.0mL loop and injected onto Hiload 16/600
Superdex 200 10/300 PG equilibrated in 20mM Tris pH
8.0/150mM NaCl.
20. Monomeric protein elutes80mL, and 1mL peak fractions are pooled
and concentrated in Spin-X® UF 20mL Concentrator with 30,000
molecular weight cutoff until protein reaches 10mg/mL.
21. Protein purity is accessed by a 10% SDS-PAGE gel run at 150V for
75min.
22. Purified protein is slowly dripped from a transfer pipette into liquid N2
in a shallow dewar. The protein beads are typically 25μL. The pro-
tein beads are collected into a cryocooled microcentrifuge tube held
with vial clamps, and subsequently placed in 80°C freezer.
2.3.4 Notes
1. For cell lysis, our lab usually both sonicates and then uses the French
press. Sonication is used to make the sample more homogeneous, which
makes using the French press easier. Just make sure not to overheat the
lysate solution.
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2. The expression yield of 8R-LOX psWT is robust so do not be afraid to
cutoff shoulders of protein peaks. We see more reproducible crystal
growth conditions for 8R-LOX psWT when we keep only the peaks
from the chromatography runs.
3. When freezing the purified 8R-LOX psWT into liquidN2, drip the pro-
tein just a few drops at a time. This allows for independent freezing of the
protein drops instead of protein drops coming together to make larger
aliquots.
4. After placing protein drops into cryocooled microcentrifuge tube, make
sure that there is no residual liquid N2 in the tube before closing. Failure
to boil all liquid N2 from the microcentrifuge tubes can result in the lid
blowing off along with your protein beads spilling onto the floor. (Hint:
I hold microcentrifuge tube in fingers for about 30 s before closing lid.
This is about the time it takes me to walk to the 80°C freezer.)
3. STRUCTURAL STUDIES OF 8R-LOX
The molecular weight of 8R-LOX at 79kDa makes crystallography
the ideal tool for structural studies, with the enzyme being too large for
NMR and too small for Cryo-EM. Crystallization of 8R-LOX or 8R-
LOX psWT has only been successful in conditions that include Ca2+, a
cofactor for the membrane-insertion loops on the N-terminal domain
(Neau et al., 2014, 2009, 2007; Oldham et al., 2005). To get an enzyme:sub-
strate complex trapped, the crystals must be grown in an anaerobic environ-
ment. LOXs insert molecular O2 on the fatty acid, so growing 8R-LOX
psWT crystals in an anaerobic environment is the first step to obtaining
an enzyme:substrate complex. The second step is soaking these anaerobic
crystals with AA in a glove box and cryocooling in the anaerobic environ-
ment before X-ray data collection.
3.1 Anaerobic Crystallization of 8R-LOX
3.1.1 Equipment
• Vinyl anaerobic chamber (Coy Laboratory Products)
• Sitting drop crystallization plate, such as the Cryschem Plate (Hampton
Research)
• Crystal Clear Sealing Tape or Crystal Clear Sealing Film (Hampton
Research)
• Mounted cryoloop for crystal harvesting (Hampton Research)
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3.1.2 Buffers and Reagents
• 10mg/mL 8R-LOX psWT in 150mM NaCl, 20mM Tris, pH 8.0
• 25% (w/v) PEG-8000 (FLUKA brand)
• 50% (v/v) Glycerol
• 2 M CaCl2
• 1 M Imidazole acetate, pH 8.0
3.1.3 Procedure (Carried Out Inside the Anaerobic Chamber)
1. Crystallization reagents and buffers should be degassed before bringing
them into the anaerobic chamber. Solutions should be transferred to
the anaerobic chamber immediately after degassing to keep them from
absorbing oxygen. Two alternative methods of degassing are presented
below.
a. Solutions can be degassed by placing them into a round bottom flask
and pulling a slight vacuum on the flask while stirring or sonicating
the solution and then refilling the flask with an inert gas, such as
nitrogen or argon. This should be done 3–5 times, pulling the vac-
uum for about 5min each time before refilling with the inert gas.
b. Solutions can also be degassed by sealing them in a flask and bubbling
an inert gas through the solution while sonicating for 30min to an
hour.
2. In the well of the crystallization tray, mix the following amounts of the
crystallization reagents:
• 200–320μL 25% PEG-8000 (200μL in first row, increase by 40μL
each row after)
• 100μL 50% Glycerol
• 100μL 2M CaCl2
• 100μL Imidazole acetate, pH 8.0
• Bring volume of well to 1000μL by addition of deionized water
This creates well solutions of 5%–8% PEG-8000, 5% glycerol,
0.2M CaCl2, and 0.1 M imidazole acetate, pH 8.0
3. Place 4μL of 10mg/mL 8R-LOX psWT on all of the pedestals of the
crystallization plates, then immediately pipette 4μL of well solution into
the protein drop.
4. Seal the top of the crystallization plate using either clear sealing tape or
clear sealing film.
5. Incubate the trays at room temperature. Crystals should appear in
1–2 days. Crystals typically grow with a rod-shaped, rhombic crystal
habit. Occasionally the crystals will appear more blocky than rod-like.
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6. Cryosolution for cooling of crystals is prepared by mixing 500μL of 50%
glycerol, 400μL of 25% PEG-8000, 10μL of 2M CaCl2, and 100μL of
imidazole acetate, pH 8.0 (final solution is approximately 25% glycerol,
10% PEG-8000, 0.02M CaCl2, 0.1M imidazole acetate, pH 8.0).
7. Crystals are prepped for data collection by using a sharp blade to cut away
the sealing film over a crystallization drop then looping a crystal from the
crystallization drop with a mounted cryoloop and transferring it into a
small drop (5–10μL) of cryosolution. The crystal can then be immedi-
ately looped again and plunged into liquid N2 to vitrify the crystal.
3.1.4 Notes
1. Aerobic crystals of 8R-LOX psWT can be grown using the same pro-
cedure as above, simply set up trays outside of the anaerobic chamber.
In this case, solutions do not need to be degassed and crystals can be
grown in hanging drop crystals plates as an alternative to the sitting drop
plates.
2. It is not feasible to degas the protein solution. Simply transfer the amount
of protein needed for crystallization into the anaerobic chamber in an
open Eppendorf tube.
3. Liquid N2 can be brought into the anaerobic chamber in a bowl dewar.
When taking the liquid N2 through the antechamber it has a tendency to
boil violently during the first purge cycle of the antechamber. If this boil-
ing causes too much liquid N2 to spill in the antechamber, it will vola-
tilize quickly enough to overpressure the antechamber, potentially
contaminating the anaerobic chamber. To minimize this risk, pull vac-
uum slowly during the first purge cycle if the vacuum is manually con-
trolled. Liquid N2 tends to make the oxygen level rise in the anaerobic
chamber as it boils off. As long as oxygen stays below 50ppm, the sys-
tem should still be considered anaerobic.
3.2 Preparation of 8R-LOX:AA Binary Complexes
3.2.1 Equipment
• Small plastic petri dishes (1.5–2 in. in diameter)
• Syringe of vacuum grease. Hint: use a normal plastic syringe (maybe 5 or
10 cc) filled with vacuum grease and place a P200 pipette on the tip of the
syringe for fine control as an applicator.
3.2.2 Materials
• Anaerobic 8R-LOX psWT crystals
• Arachidonic acid
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• Anaerobic 8R-LOX psWT cryosolution: 25% glycerol, 10% PEG-8000,
0.02M CaCl2, 0.1M imidazole acetate, pH 8.0
• DMSO
3.2.3 Procedure (Carried Out Inside the Anaerobic Chamber)
1. Dilute AA to 100mg/mL using DMSO.
2. Dilute the AA further to 1mg/mL by adding 1μL of the 100mg/mL AA
solution to 99μL of the 8R-LOX psWT cryosolution.
3. Apply a bead of vacuum grease to the inside edge of the lid of the
petri dish.
4. Place 1.0mL of 8R-LOX psWT cryosolution into the bottom of the
petri dish.
5. Put a 5.0μL drop of the 1mg/mL AA solution on the inside surface of
the lid of the petri dish.
6. Using a mounted cryoloop, transfer an anaerobic 8R-LOX psWT crystal
into the drop of AA solution.
7. Invert the lid and seal it onto the bottom of the petri dish, so that the drop
containing the crystal is suspended over the 1.0mL of cryosolution. The
1.0mL of cryosolution prevents the soaking drop from drying out.
8. Allow the crystal to soak overnight (16h).
9. Loop the crystal from the soaking drop and immediately plunge into liq-
uid nitrogen.
3.2.4 Notes
1. Cocrystallization of 8R-LOX psWT with AA has not been successful.
A relatively high concentration of CaCl2 is required to crystallize 8R-
LOX, and AA is insoluble when at this concentration of CaCl2.
2. Trinary complexes of 8R-LOX, AA, and Xenon (an oxygen mimic)
should be achievable by preparing the binary complex as above and then
transferring the soaked crystals into a Xenon pressurization chamber.
4. SUMMARY AND CONCLUSIONS
The 8R-LOX from P. homomalla is an excellent model enzyme for
animal LOXs due to its robust overexpression and inherent protein stability.
Our lab’s undergraduate research students routinely execute the expression
and purification of 8R-LOX psWT. These aforementioned methods are
used as a training manual for new students, and these methods form the
foundation for developing expression and purification protocols for addi-
tional LOX enzymes. Our current understanding of animal LOXs has been
47Expression of an 8R-Lipoxygenase
greatly expanded with the multiple crystal structures of 8R-LOX, 8R-LOX
psWT, and 8R-LOX psWT with substrate.
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